Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 123,792

Document Document Title
WO/2017/087691A1
Methods for prophylactically treating a stress-induced affective disorder or stress- induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain em...  
WO/2017/087863A1
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions ar...  
WO/2017/085733A2
The disclosure herein provides a composition of compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1 and its improved processes. The compound of formula 1 or its pharmaceutical acceptable...  
WO/2017/085484A1
The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the ...  
WO/2017/087858A1
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions ar...  
WO/2017/085844A1
[Problem] To provide a pharmaceutical preparation and food/drink containing a β-secretase inhibitor that is highly safe and that exhibits a better inhibitory effect on β-secretase activity. [Solution] Provided is a β-secretase inhibit...  
WO/2017/086303A1
The purpose of the present invention is to provide a peptide composition that includes a functional peptide. The present invention provides a peptide composition that includes one or more components selected from the group consisting of:...  
WO/2017/081296A1
This invention relates to a novel therapeutic approach for treating demyelinating diseases such as multiple sclerosis (MS) and for treating conditions associated with white matter ischaemia. Ion channel modulators for use in such treatme...  
WO/2017/081483A1
The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions contai...  
WO/2017/082827A1
A non-saccharide glycosaminoglycan mimetic molecule comprising a polyproline backbone and one or more non- saccharide molecules, wherein the non-saccharide molecules are bound to one or more prolines and/or proline derivatives on the pol...  
WO/2017/079832A1
The disclosure pertains to C-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/082288A1
A compound represented by any one of formulae (I) to (XXII), or a pharmaceutically acceptable salt thereof.  
WO/2017/083795A1
Disclosed are methods and compositions for treating alcohol dependence by administration to a patient of an inhibitor of 11β-hydroxysteroid dehydrogenases (11β-HSD) to modulate glucocorticoid effects. One such compound is the 11β-HSD ...  
WO/2017/079831A1
The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/079835A1
The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/081609A1
The therapeutic uses of febuxostat or febuxostat derivatives and compositions comprising febuxostat or febuxostat derivatives to promote neurogenesis for the treatment of disease.  
WO/2017/082396A1
The purpose of the present invention is to provide a method for the industrial production of lacosamide having high optical purity at a high yield, inexpensively, and safely. Provided is a method for the industrial production of lacosami...  
WO/2017/083700A1
Disclosed are conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand. Disclosed are methods of clearing amyloid beta aggregates from a subject comprising administering a therapeutically effect...  
WO/2017/079833A1
The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/080967A1
The present invention provides pharmaceutical compositions comprising a compound of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is conc...  
WO/2017/079834A1
The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/082121A1
This sustained-release topically administered agent includes: a compound having a pharmacological action; a crosslinkable polysaccharide derivative in which at least one active ester group capable of reacting with an active hydrogen-cont...  
WO/2017/078175A1
The present invention relates to an enhancer of the anti-dementia activity of royal jelly, which comprises limonene.  
WO/2017/077082A1
The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of su...  
WO/2017/076356A1
Disclosed are a novel crystal form of Flibaserin, and a preparation method therefor. The novel crystal form of Flibaserin of the present invention is named a crystal form I and a crystal form II. Compared with an existing crystal form, t...  
WO/2017/079455A1
Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of t...  
WO/2017/079734A1
Methods and pharmaceutical compositions are provided, which make use of compounds disclosed herein, including (I). The methods and compositions are useful for producing local or regional anesthesia or analgesia in nerve tissue of a subject.  
WO/2017/076900A1
The present invention relates to a novel [l,2,4]triazolo[l,5-a]pyrimidin-yl derivative of formula (1) as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to p...  
WO/2017/076932A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from (II) R1 is S(0)2lower alkyl, S(0)2NR4R5, S(0)2c...  
WO/2017/077284A1
The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a ...  
WO/2017/075661A1
The present invention relates to methods and compositions for treating a condition associated with, or arising from, astrocyte dysfunction or glial scar formation or progression in an individual. The present invention is useful for, but ...  
WO/2017/079519A1
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, car...  
WO/2017/079391A1
The present invention provides compounds of Formula I and Formula II, and related compositions and methods.  
WO/2017/079161A3
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiat...  
WO/2017/076738A1
The present invention relates to a new process for preparing brivaracetam. (Ib)  
WO/2017/076825A1
The present invention provides (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2- (pyrimidin-2-yl)-4-(trifluoromethyl)thiazole-5-carboxamide as P2X7 inhibitor, its use as a medicament, and a convenient enantiomeric synthesis protocol for th...  
WO/2017/077336A1
Polymeric nanoparticles comprising disulfiram or derivatives thereof, and their use in the treatment of cancer.  
WO/2017/075729A1
The present invention relates to an AAV/UPR-plus virus sequence, to a genetic treatment method, and to the use thereof in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, inter alia, as s...  
WO/2017/076737A1
The present invention relates to a continuous flow process for preparing brivaracetam.  
WO/2017/076169A1
The present invention provides a baicalein caffeine eutectic crystal, a preparation method therefor, a pharmaceutical composition, and application thereof. The baicalein caffeine eutectic crystal of the present invention has an excellent...  
WO/2017/076852A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and nega...  
WO/2017/079467A1
Methods of the invention encompass delivery of nucleic acid sequences encoding ABCD1 for the treatment of X-linked Adrenoleukodystrophy (X-ALD), e.g., for Adrenomyeloneuropathy (AMN).  
WO/2017/077292A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic Μ1 and M4 receptors. Also provided are pharmaceutical composition...  
WO/2017/079641A1
Provided herein are small molecule compounds of the following formula (I): or a stereoisomer, tautomer, solvate, ester or pharmaceutically acceptable salt thereof, wherein A, B, C, Li, L 2, Ri, R 2, R 3, R 4, R 5, w, x, y and z are as de...  
WO/2017/076842A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and nega...  
WO/2017/076931A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from or the oxygen atom may form together with two n...  
WO/2017/075610A1
The present specification provides methods of treating nervous system disorders with a thyroid hormone neutral dose of a RXR agonist to promote remyelination or neuroprotection or both and thereby maintain or regenerate healthy axons and...  
WO/2017/073232A1
The present invention addresses the problem of providing a neural vascular barrier failure inhibitor, said inhibitor acting on vascular barrier failures caused not only by a hypoxic state but also by various other factors, and a therapeu...  
WO/2017/071536A1
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2017/073709A1
A compound represented by formula (1) or salt thereof which has an inhibitory effect on mPGES-1, and is useful as an active ingredient for a medicinal drug for preventing and/or treating a disease such as inflammation, pain, rheumatism, ...  

Matches 251 - 300 out of 123,792